From synthesis to pill without pause


Play all audios:

Access through your institution Buy or subscribe A factory that produces a continuous stream of drug tablets from the raw ingredients could save time and money over traditional stop–start


methods, which spread manufacture over many locations. Bernhardt Trout and his colleagues at the Massachusetts Institute of Technology in Cambridge report the first example of such a plant,


an 18-square-metre factory that produces the hypertension drug aliskiren (developed by Novartis, which funded the project). Chemical building blocks flow in at one end, followed by a series


of reactions and separations in which the drug is synthesized, crystallized, dried and coated to produce tablets at the other. This is a preview of subscription content, access via your


institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 51 print issues and online access $199.00 per year only $3.90 per issue Learn more Buy this


article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in


* Learn about institutional subscriptions * Read our FAQs * Contact customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE From synthesis to


pill without pause. _Nature_ 502, 274 (2013). https://doi.org/10.1038/502274d Download citation * Published: 16 October 2013 * Issue Date: 17 October 2013 * DOI:


https://doi.org/10.1038/502274d SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently


available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative